<DOC>
	<DOC>NCT02478060</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and tolerability of multiple administrations of Birch-SPIRE. To make a preliminary assessment on pharmacodynamic parameters and clinical outcomes.</brief_summary>
	<brief_title>Birch-SPIRE Safety and Efficacy Study</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis</mesh_term>
	<criteria>Male or female, aged 18 to 65 years; Minimum 1 year history of rhinitis with or without conjunctivitis on exposure to birch pollen Birch IgE â‰¥ 0.35 kU/L Positive skin prick test to whole birch allergen Any past history of asthma FEV1 &lt; 80% of predicted History of severe allergic reaction to birch allergen, severe drug allergy, severe angioedema or severe allergic reactions to food Acute phase skin response to whole birch allergen with a mean wheal diameter &gt; 50mm Administration of adrenaline (epinephrine) is contraindicated History of severe drug allergy or anaphylactic reaction to food. History of any significant disease or disorder (e.g. immune system, pulmonary, cardiovascular, gastrointestinal, liver, renal, neurological, metabolic, malignant, psychiatric, major physical impairment, history of alcohol or drug abuse)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Allergy</keyword>
	<keyword>Birch</keyword>
	<keyword>Rhinitis</keyword>
	<keyword>Rhinoconjuntivitis</keyword>
	<keyword>SPIRE</keyword>
	<keyword>Toleromune</keyword>
</DOC>